BCAL Expands National Access for Early Cancer Detection Tests
BCAL Diagnostics Limited (ASX: BDX) has strengthened its commercial rollout strategy by expanding access to its early cancer detection portfolio across Australia. The company integrated referral pathways into major GP software systems, including Best Practice and Medical Director, enabling access to nearly 97% of Australian general practitioners. The healthcare company also launched its telehealth platform, EarlyDetection.com.au, in partnership with Medmate, creating an additional pathway for patients to access blood-based cancer screening services. BCAL further expanded its infrastructure through a Sydney CBD clinic focused on high-risk patient assessment and testing.
Its growing diagnostics portfolio includes BREASTESTplus™, Avantect® Pancreatic, Avantect® Ovarian, and a multi-cancer early detection test expected to launch in June 2026. Management highlighted the pancreatic cancer testing opportunity, estimating the Australian addressable market at more than A$250 million annually. The company also registered its EarlyDetection platform across several international markets, including New Zealand, the United Kingdom, the United States, and India, supporting future global expansion plans.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
BCAL Expands National Access for Early Cancer Detection Tests
BCAL Diagnostics Limited (ASX: BDX) has strengthened its commercial rollout strategy by expanding access to its early cancer detection portfolio across Australia. The company integrated referral pathways into major GP software systems, including Best Practice and Medical Director, enabling access to nearly 97% of Australian general practitioners. The healthcare company also launched its telehealth platform, EarlyDetection.com.au, in partnership with Medmate, creating an additional pathway for patients to access blood-based cancer screening services. BCAL further expanded its infrastructure through a Sydney CBD clinic focused on high-risk patient assessment and testing.
Its growing diagnostics portfolio includes BREASTESTplus™, Avantect® Pancreatic, Avantect® Ovarian, and a multi-cancer early detection test expected to launch in June 2026. Management highlighted the pancreatic cancer testing opportunity, estimating the Australian addressable market at more than A$250 million annually. The company also registered its EarlyDetection platform across several international markets, including New Zealand, the United Kingdom, the United States, and India, supporting future global expansion plans.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au